Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Return on Total Capital (ROTC) for the year ending December 31, 2023

Aerovate Therapeutics Inc Return on Total Capital (ROTC) is NA for the year ending December 31, 2023. Return on total capital measures the profitability of a company relative to its total capital, which includes total debt and shareholders' equity. It is calculated by dividing the net income by the sum of total debt and shareholders' equity. This ratio provides insights into the return generated for each unit of total capital invested in the company. A higher return on total capital indicates better profitability and efficient utilization of both debt and equity capital.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email